1-h-pyrrolo[2,3-c]pyridine compounds acting against cancer via agonism of menin
Patent Information
- Application Number
- HK62026127078
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-03-24
- Filing Date
- 2026-08-05
- Publication Date
- 2026-09-11
Smart Images

Figure 00000399_0000 
Figure 00000400_0000 
Figure 00000401_0000
Abstract
Description
This invention discloses compounds having the structure of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and A are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts for the treatment or prevention of Menin-mediated conditions; kits comprising such compounds and salts; and methods for preparing such compounds and salts. Abstract
Claims
What is claimed is:
1. A compound having the structure of Formula (I):or a pharmaceutically acceptable salt thereof, wherein:R1is selected from the group consisting of hydrogen and methyl;R2is hydrogen or fluoro;R3is hydrogen or fluoro;R4is selected from the group consisting of:(a) -C(O)NR5R6;(b) phenyl optionally substituted with one to three substituents independently selected from the group consisting of fluoro, cyano, C1-4-alkyl, halo-C1-4-alkyl, C3-4-cycloalkyl, and halo-C3-4- cycloalkyl; and(c) 5- or 6-membered ring heteroaryl having one, two, or three ring atoms independently selected from nitrogen, oxygen, and sulfur with the remaining ring atoms being carbon, wherein the heteroaryl is optionally substituted with one to three substituents independently selected from the group consisting of fluoro, cyano, C1-4-alkyl, halo-C1-4-alkyl, C3-4-cycloalkyl, and halo-C3-4- cycloalkyl;R5and R6are independently selected from C1-4-alkyl and halo-C1-4-alkyl; or R5and R6, together with the nitrogen atom to which they are attached, form a 5- to 7-membered ring heterocyclyl, wherein the heterocyclyl: (i) is a saturated monocyclic ring, (ii) has one or two ring atoms independently selected from nitrogen and oxygen with the remaining ring atoms being carbon, and (iii) is optionally substituted with one to three substituents independently selected from the group consisting of C1-4-alkyl and halo-C1-4-alkyl;X is -C(R9)- or -N-;R9is selected from the group consisting of hydrogen, fluorine, and methyl;A is selected from the group consisting of:each RAsubstituent is optionally and independently selected from the group consisting of fluoro and C1-4-alkyl; r is 0, 1, or 2; s is 0, 1, 2, or 3; t is 0, 1, 2, 3, or 4; u is 0, 1, 2, 3, 4, or 5;R10is selected from the group consisting of C1-10-alkyl, -CH2R11, or -C(O)R12; wherein the C1-10-alkyl is substituted with one or more -NR13R14;R11is cyclohexyl optionally substituted with one or more substituents independently selected from the group consisting of C1-4-alkyl, -NR15R16, and -N(R17)S(O)2R18;R12is 5- to 10-membered ring heterocyclyl, wherein the heterocyclyl: (i) is a saturated or partially saturated monocyclic ring, bicyclic ring, or spirocyclic ring system, (ii) has one or two nitrogen ring atoms with the remaining ring atoms being carbon, and (iii) is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, C1-4-alkyl, halo-C1-4-alkyl, C1-4-alkenyl, -OR19, -NR20R21, and -N(R22)S(O)2R23;R13and R14are independently selected from the group consisting of C1-6-alkyl and C1-6-alkoxy-C1-6-alkyl; andR15, R16, R17, R18, R19, R20, R21, R22, and R23are independently selected from the group consisting of hydrogen and C1-4-alkyl.
2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound has the structure of Formula (I- A):and wherein R2, R3, R4, and A are as defined in claim 1.
3. The compound of claim 1 or claim 2, or a pharmaceutically acceptable salt thereof, wherein R3is fluoro.
4. The compound of any of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein X is -C(R9)-.
5. The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein R9is hydrogen.
6. The compound of any of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein R2is hydrogen.
7. The compound of any of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein R1is methyl.
8. The compound of any of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R4is -C(O)NR5R6.
9. The compound of claim 8, or a pharmaceutically acceptable salt thereof, wherein R5and R6are independently selected from C1-4-alkyl and halo-C1-4-alkyl.
10. The compound of claim 8, or a pharmaceutically acceptable salt thereof, wherein R5and R6, together with the nitrogen atom to which they are attached, form a 5- to 7-membered ring heterocyclyl, wherein the heterocyclyl: (i) is a saturated monocyclic ring, (ii) has one or two ring atoms independently selected from nitrogen and oxygen with the remaining ring atoms being carbon, and (iii) is optionally substituted with one to three substituents independently selected from the group consisting of C1-4-alkyl and halo-C1-4-alkyl.
11. The compound of any of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R4is 5- or 6-membered ring heteroaryl having one, two, or three ring atoms independently selected from nitrogen, oxygen, and sulfur with the remaining ring atoms being carbon, wherein the heteroaryl is optionally substituted with one to three substituents independently selected from the group consisting of fluoro, cyano, C1-4-alkyl, halo-C1-4-alkyl, C3-4-cycloalkyl, and halo-C3-4- cycloalkyl.
12. The compound of any of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein:R4is selected from the group consisting of:(a) -C(O)NR5R6; and(b) 5- or 6-membered ring heteroaryl having one, two, or three ring atoms selected from nitrogen, oxygen, and sulfur with the remaining ring atoms being carbon, wherein the heteroaryl isoptionally substituted with one to three substituents independently selected from the group consisting of fluoro, cyano, C1-4-alkyl, halo-C1-4-alkyl, C3-4-cycloalkyl, and halo-C3-4-cycloalkyl; andR5and R6are independently selected from C1-4-alkyl and halo-C1-4-alkyl; or R5and R6, together with the nitrogen atom to which they are attached, form a 5- to 7-membered ring heterocyclyl, wherein the heterocyclyl: (i) is a saturated monocyclic ring, (ii) has one or two ring atoms independently selected from nitrogen and oxygen with the remaining ring atoms being carbon, and (iii) is optionally substituted with one to three substituents independently selected from the group consisting of C1-4-alkyl and halo-C1-4-alkyl.
13. The compound of any of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein r, s, t, and u are 0.
14. The compound of any of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein A is:
15. The compound of any of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein:R10is C1-10-alkyl substituted with one or more -NR13R14; andR13and R14are independently selected from the group consisting of C1-6-alkyl and C1-6-alkoxy-C1-6-alkyl.
16. The compound of any of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein:R10is -C(O)R12;R12is 5- to 10-membered ring heterocyclyl, wherein the heterocyclyl: (i) is a saturated or partially saturated monocyclic ring, bicyclic ring, or spirocyclic ring system, (ii) has one or two nitrogen ring atoms with the remaining ring atoms being carbon, and (iii) is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, C1-4-alkyl, halo-C1-4-alkyl, C1-4-alkenyl, -OR19, -NR20R21, and -N(R22)S(O)2R23; andR19, R20, R21, R22, and R23are independently selected from the group consisting of hydrogen and C1-4-alkyl.
17. The compound of claim 16, or a pharmaceutically acceptable salt thereof: wherein the R12heterocyclyl is selected from the group consisting of:wherein the R12heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, C1-4-alkyl, halo-C1-4-alkyl, C1-4-alkenyl, -OR19, - NR20R21, and -N(R22)S(O)2R23; wherein R19, R20, R21, R22, and R23are independently selected from the group consisting of hydrogen and C1-4-alkyl.
18. The compound of claim 16, or a pharmaceutically acceptable salt thereof, wherein the R12heterocyclyl is:and is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, C1-4-alkyl, halo-C1-4-alkyl, C1-4-alkenyl, -OR19, -NR20R21, and -N(R22)S(O)2R23; wherein R19, R20, R21, R22, and R23are independently selected from the group consisting of hydrogen and C1-4-alkyl.
19. The compound of any of claims 16 to 18, or a pharmaceutically acceptable salt thereof, wherein the R12heterocyclyl is optionally substituted with one or more C1-4-alkyl.
20. The compound of any of claims 16 to 18, or a pharmaceutically acceptable salt thereof, wherein the R12heterocyclyl is optionally substituted with one or more methyl.
21. The compound of claim 16, or a pharmaceutically acceptable salt thereof, wherein the R12heterocyclyl is selected from the group consisting of:
22. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein: the compound has a structure selected from the group consisting of:wherein, as applicable:R1, R4, R5, R6, R10, R11, R12, X, A, RA, r, s, and t are as defined in claim 1;the R4phenyl present in the structures of Formula 1-54 through Formula 1-57 is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, cyano, C1-4-alkyl, halo-C1-4-alkyl, C3-4-cycloalkyl, and halo-C3-4-cycloalkyl; the R4pyrazolyl, pyridinyl, and pyrimidinyl present in the structures of Formula 1-58 through Formula 1-69 are optionally substituted with one or more substituents independently selected from the group consisting of fluoro, cyano, C1-4-alkyl, halo-C1-4-alkyl, C3-4-cycloalkyl, and halo-C3-4- cycloalkyl; the R11cyclohexyl present in the structure of Formula 1-53 is optionally substituted with one or more substituents independently selected from the group consisting of C1-4-alkyl, -NR15R16, and - N(R17)S(O)2R18; the R12heterocyclyl present in the structures of Formula 1-43 through Formula 1-52 is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, C1-4-alkyl, halo-C1-4-alkyl, C1-4-alkenyl, -OR19, -NR20R21, and -N(R22)S(O)2R23; andR15, R16, R17, R18, R19, R20, R21, R22, and R23are independently selected from the group consisting of hydrogen and C1-4-alkyl.
23. The compound of claim 22, or a pharmaceutically acceptable salt thereof, wherein:R1is methyl; r, s, and t are each 0; the structure is selected from Formula 1-43 through Formula 1-52; the R12heterocyclyl present in the structure is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, C1-4-alkyl, halo-C1-4-alkyl, C1-4-alkenyl, -OR19, -NR20R21, and -N(R22)S(O)2R23; andR19, R20, R21, R22, and R23are independently selected from the group consisting of hydrogen and C1-4-alkyl.
24. The compound of claim 22, or a pharmaceutically acceptable salt thereof, wherein:R1is methyl; r, s, and t are each 0; the structure is selected from Formula 1-43 through Formula 1-52; and the R12heterocyclyl present in the structure is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, C1-4-alkyl, halo-C1-4-alkyl, and C1-4-alkenyl.
25. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has the structure of Formula 1-5 A:R4and A are as defined in claim 1.
26. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound has the structure of Formula I-33A:R4, R12, RA, and t are as defined in claim 1.
27. The compound of claim 26, or a pharmaceutically acceptable salt thereof, wherein t is 0.
28. The compound of claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:5-Fluoro-N,N-diisopropyl-2-(3-((S)-1-(((lr,4S)-4-(methylsulfonamido)-cyclohexyl)- methyl)pyrrolidine-3-carbonyl)- 1H-pyrrolo[2,3-c]pyridin- 1 -yl)benzamide [Example 1 ] ;2-(3-((S)-1-((lR,3S,4S)-2-Azabicyclo[2.2.1]heptane-3-carbonyl)pyrrolidine-3-carbonyl)-1H- pyrrolo[2,3-c]pyridin-1-yl)-5-fluoro-N,N-diisopropylbenzamide [Example 2];2-(3-((R)-1-((lR,3S,4S)-2-Azabicyclo[2.2.1]heptane-3-carbonyl)pyrrolidine-3-carbonyl)-1H- pyrrolo[2,3-c]pyridin-1-yl)-5-fluoro-N,N-diisopropylbenzamide [Example 3];5-Fluoro-N,N-diisopropyl-2-(3-((R)-1-(((lr,4R)-4-(methylsulfonamido)cyclohexyl)- methyl)pyrrolidine-3-carbonyl)- 1H-pyrrolo[2,3-c]pyridin- 1 -yl)benzamide [Example 4] ;2-(3-(1-((lR,3S,4S)-2-Azabicyclo[2.2.1]heptane-3-carbonyl)azetidine-3-carbonyl)-1H- pyrrolo[2,3-c]pyridin-1-yl)-5-fluoro-N,N-diisopropylbenzamide [Example 5];(S)-2-(3-(1-(2-Azabicyclo[2.2.2]octane-3-carbonyl)azetidine-3-carbonyl)-1H-pyrrolo-[2,3- c]pyridin-1-yl)-5-fluoro-N,N-diisopropylbenzamide [Example 6];5-Fluoro-2-(3-(1-((1S,3S,4S,5S)-5-fluoro-2-azabicyclo[2.2.1]heptane-3-carbonyl)-azetidine- 3-carbonyl)- 1H-pyrrolo[2,3-c]pyridin- 1 -yl)-N,N-diisopropylbenzamide [Example 7] ;2-(3-(1-((lR,3S,4S)-2-Azabicyclo[2.2.1]heptane-3-carbonyl)azetidine-3-carbonyl)-1H- pyrrolo[2,3-c]pyridin-1-yl)-N-ethyl-5-fluoro-N-isopropylbenzamide [Example 8];(S)-2-(3-(1-(2-Azabicyclo[2.2.2]octane-3-carbonyl)azetidine-3-carbonyl)-1H-pyrrolo-[2,3- c]pyridin- 1 -yl)-N-ethyl-5 -fluoro-N -isopropylbenzamide [Example 9] ;(1-((lR,3S,4S)-2-Azabicyclo[2.2.1]heptane-3-carbonyl)azetidin-3-yl)(1-(4-fluoro-2-(2- isopropylpyridin-3-yl)phenyl)- 1H-pyrrolo[2,3-c]pyridin-3-yl)methanone [Example 10] ;(1-((lR,3S,4S)-2-Azabicyclo[2.2.1]heptane-3-carbonyl)azetidin-3-yl)(1-(4-fluoro-2-(3- isopropylpyridin-4-yl)phenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl)methanone 1 • formic acid [Example 11];(1-((lR,3S,4S)-2-Azabicyclo[2.2.1]heptane-3-carbonyl)azetidin-3-yl)(1-(4-fluoro-2-(4- isopropylthiazol-5-yl)phenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl)methanone 1 • formic acid [Example 12];(1-((lR,3S,4S)-2-Azabicyclo[2.2.1]heptane-3-carbonyl)azetidin-3-yl)(1-(4-fluoro-2-(2-(2- fluoropropan-2-yl)pyridin-3-yl)phenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl)methanone [Example 13];2-(5-(1-((lR,3S,4S)-2-Azabicyclo[2.2.1]heptane-3-carbonyl)azetidine-3-carbonyl)-7H- pyrrolo[2,3-c]pyridazin-7-yl)-5-fluoro-N,N-diisopropylbenzamide 1 • formic acid [Example 14];2-(3-(1-((lR,3S,4S)-2-Azabicyclo[2.2.1]heptane-3-carbonyl)azetidine-3-carbonyl)-7-fluoro- 1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluoro-N,N-diisopropylbenzamide [Example 15];2-(3-(1-((lR,3S,4S)-2-Azabicyclo[2.2.1]heptane-3-carbonyl)piperidine-4-carbonyl)-1H- pyrrolo[2,3-c]pyridin- 1 -yl)-5-fluoro-N,N-diisopropylbenzamide [Example 16] ;5-Fluoro-N,N-diisopropyl-2-(3-(1-(((lr,4r)-4-(methylsulfonamido)cyclohexyl)methyl)- piperidine-4-carbonyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamide [Example 17];5-Fluoro-N,N-diisopropyl-2-(3-(1-((1S,3S,4R)-5-methylene-2-azabicyclo[2.2.2]octane-3- carbonyl)piperidine-4-carbonyl)- 1H-pyrrolo[2,3-c]pyridin- 1 -yl)benzamide [Example 18] ;2-(3-(1-((1S,2S , 5R)-3 - Azabicyclo[3.1.0]hexane-2-carbonyl)piperidine-4-carbonyl)- 1H- pyrrolo[2,3-c]pyridin-1-yl)-5-fluoro-N,N-diisopropylbenzamide [Example 19];(S)-2-(3-(1-(2-Azabicyclo[2.2.2]octane-3-carbonyl)piperidine-4-carbonyl)-1H-pyrrolo[2,3- c]pyridin-1-yl)-5-fluoro-N,N-diisopropylbenzamide [Example 20];5-Fluoro-N,N-diisopropyl-2-(3-(1-((1S,3aR,6aS)-octahydrocyclopenta[c]pyrrole-1- carbonyl)piperidine-4-carbonyl)- 1H-pyrrolo[2,3-c]pyridin- 1 -yl)benzamide [Example 21];5-Fluoro-2-(3-(1-((1S,3S,4S,5S)-5-fluoro-2-azabicyclo[2.2.1]heptane-3-carbonyl)- piperidine-4-carbonyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-N,N-diisopropylbenzamide [Example 22]; rac-(R)-5-Fluoro-N,N-diisopropyl-2-(3-(1-(6-((2-methoxyethyl)(methyl)amino)-2- methylhexan-3-yl)piperidine-4-carbonyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamide [Example 23];(S)-2-(3-(1-(4-Azaspiro[2.4]heptane-5-carbonyl)piperidine-4-carbonyl)-1H-pyrrolo[2,3- c]pyridin-1-yl)-5-fluoro-N,N-diisopropylbenzamide [Example 24]; rel-2-(3-(1-((lR,2R,5S)-3-Azabicyclo[3.2.0]heptane-2-carbonyl)piperidine-4-carbonyl)-1H- pyrrolo[2,3-c]pyridin-1-yl)-5-fluoro-N,N-diisopropylbenzamide [Example 25];(S)-2-(3-(1-(5-Azaspiro[2.4]heptane-6-carbonyl)piperidine-4-carbonyl)-1H-pyrrolo[2,3- c]pyridin-1-yl)-5-fluoro-N,N-diisopropylbenzamide [Example 26];(S)-2-(3-(1-(5,5-Dimethylpyrrolidine-2-carbonyl)piperidine-4-carbonyl)-1H-pyrrolo[2,3- c]pyridin-1-yl)-5-fluoro-N,N-diisopropylbenzamide [Example 27];2-(3-(1-((1S,2S , 5R)-3 - Azabicyclo[3.1.0]hexane-2-carbonyl)piperidine-4-carbonyl)- 1H- pyrrolo[2,3-c]pyridin-1-yl)-N-ethyl-5-fluoro-N-isopropylbenzamide [Example 28];(S)-2-(3-(1-(2-Azabicyclo[2.2.2]octane-3-carbonyl)piperidine-4-carbonyl)-1H-pyrrolo[2,3- c]pyridin-1-yl)-N-ethyl-5-fluoro-N-isopropylbenzamide [Example 29];N-Ethyl-5-fluoro-2-(3-(1-((1S,3S,4S,5S)-5-fluoro-2-azabicyclo[2.2.1]heptane-3- carbonyl)piperidine-4-carbonyl)- 1H-pyrrolo[2,3-c]pyridin- 1 -yl)-N-isopropylbenzamide [Example 30];2-(3-(1-((lR,3S,4S)-2-Azabicyclo[2.2.1]heptane-3-carbonyl)piperidine-4-carbonyl)-1H- pyrrolo[2,3-c]pyridin-1-yl)-N-ethyl-5-fluoro-N-isopropylbenzamide [Example 31];(1-((lR,3S,4S)-2-Azabicyclo[2.2.1]heptane-3-carbonyl)piperidin-4-yl)(1-(2-((2R,5S)-2,5- dimethylpyrrolidine-1-carbonyl)-4-fluorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl)methanone [Example 32];(1-((lR,3S,4S)-2-Azabicyclo[2.2.1]heptane-3-carbonyl)piperidin-4-yl)(1-(2-((2R,6S)-2,6- dimethylpiperidine-1-carbonyl)-4-fluorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl)methanone [Example 33];(1-((lR,3S,4S)-2-Azabicyclo[2.2.1]heptane-3-carbonyl)piperidin-4-yl)(1-(2-((3R,5R)-3,5- dimethylmorpholine-4-carbonyl)-4-fluorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl)methanone [Example 34];(1-((lR,3S,4S)-2-Azabicyclo[2.2.1]heptane-3-carbonyl)piperidin-4-yl)(1-(2-((3R,5S)-3,5- dimethylmorpholine-4-carbonyl)-4-fluorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl)methanone [Example 35];(1-((lR,3S,4S)-2-Azabicyclo[2.2.1]heptane-3-carbonyl)piperidin-4-yl)(1-(4-fluoro-2-(1- isopropyl-1H-pyrazol-5-yl)phenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl)methanone [Example 36];(1-((lR,3S,4S)-2-Azabicyclo[2.2.1]heptane-3-carbonyl)piperidin-4-yl)(1-(4-fluoro-2-(4- isopropylpyrimidin-5-yl)phenyl)- 1H-pyrrolo[2,3-c]pyridin-3-yl)methanone [Example 37] ;(1-((lR,3S,4S)-2-Azabicyclo[2.2.1]heptane-3-carbonyl)piperidin-4-yl)(1-(4-fluoro-2-(2- isopropylpyridin-3-yl)phenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl)methanone [Example 38];(1-((lR,3S,4S)-2-Azabicyclo[2.2.1]heptane-3-carbonyl)piperidin-4-yl)(1-(5-fluoro-2'- isopropyl-[l,l'-biphenyl]-2-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl)methanone [Example 39];(1-((lR,3S,4S)-2-Azabicyclo[2.2.1]heptane-3-carbonyl)piperidin-4-yl)(1-(2-(4- cyclopropylpyrimidin-5-yl)-4-fluorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl)methanone [Example 40];(1-((lR,3S,4S)-2-Azabicyclo[2.2.1]heptane-3-carbonyl)piperidin-4-yl)(1-(4-fluoro-2-(4- isopropylpyridin-3-yl)phenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl)methanone [Example 41];(1-((lR,3S,4S)-2-Azabicyclo[2.2.1]heptane-3-carbonyl)piperidin-4-yl)(1-(4-fluoro-2-(4- isopropylthiazol-5-yl)phenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl)methanone 1 • formic acid [Example 42];( 1 -(( 1 S,2S,5R)-3-Azabicyclo[3.1.0]hexane-2-carbonyl)piperidin-4-yl)( 1 -(4-fluoro-2-( 1 - isopropyl-1H-pyrazol-5-yl)phenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl)methanone 1 • formic acid [Example 43];2-(3-(1-((lR,3S,4S)-2-Azabicyclo[2.2.1]heptane-3-carbonyl)piperidine-4-carbonyl)-4-fluoro- 1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluoro-N,N-diisopropylbenzamide 1 • formic acid [Example 44];2-(3-((R*)-1-((lR,3S,4S)-2-Azabicyclo[2.2.1]heptane-3-carbonyl)azepane-4-carbonyl)-1H- pyrrolo[2,3-c]pyridin-1-yl)-5-fluoro-N,N-diisopropylbenzamide 1 • formic acid [Example 45];2-(3-(1-((lR,3S,4S)-2-Azabicyclo[2.2.1]heptane-3-carbonyl)piperidine-4-carbonyl)-2- methyl-1H-pyrrolo[2,3-c]pyridin-1-yl)-N-ethyl-5-fluoro-N-isopropylbenzamide [Example 46];2-(3-(1-((1S,2S,5R)-3-Azabicyclo[3.1.0]hexane-2-carbonyl)piperidine-4-carbonyl)-2-methyl- 1H-pyrrolo[2,3-c]pyridin-1-yl)-N-ethyl-5-fluoro-N-isopropylbenzamide [Example 47];2-(3-(1-((1S,2S,5R)-3-Azabicyclo[3.1.0]hexane-2-carbonyl)piperidine-4-carbonyl)-2-methyl- 1H-pyrrolo[2,3-c]pyridin-1-yl)-N-ethyl-5-fluoro-N-isopropylbenzamide [Example 48-2];(S)-2-(3-(1-(4-Azaspiro[2.4]heptane-5-carbonyl)piperidine-4-carbonyl)-2-methyl-1H- pyrrolo[2,3-c]pyridin-1-yl)-N-ethyl-5-fluoro-N-isopropylbenzamide [Example 49-2];(S)-2-(3-(1-(5,5-Dimethylpyrrolidine-2-carbonyl)piperidine-4-carbonyl)-2-methyl-1H- pyrrolo[2,3-c]pyridin-1-yl)-N-ethyl-5-fluoro-N-isopropylbenzamide [Example 50-2];2-(3-(1-((1S,2S,5R)-3-Azabicyclo[3.1.0]hexane-2-carbonyl)piperidine-4-carbonyl)-2-methyl- 1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluoro-N-isopropyl-N-(2,2,2-trifluoroethyl)benzamide [Example 51-2];N-Ethyl-5-fluoro-N-isopropyl-2-(2-methyl-3-((2R*,4S*)-2-methyl-1-((S)-4-azaspiro[2.4]- heptane-5-carbonyl)piperidine-4-carbonyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamide [Example 52- 1];N-Ethyl-5-fluoro-N-isopropyl-2-(2-methyl-3-((2R*,4S*)-2-methyl-1-((S)-4-azaspiro[2.4]- heptane-5-carbonyl)piperidine-4-carbonyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamide [Example 52- 2];2-(3-((2R*,4S*)-1-((1S,2S,5R)-3-Azabicyclo[3.1.0]hexane-2-carbonyl)-2-methyl-piperidine- 4-carbonyl)-2-methyl-1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluoro-N-isopropyl-N-(2,2,2- trifluoroethyl)benzamide [Example 53-3];2-(3-((2R*,4S*)-1-((1S,2S,5R)-3-Azabicyclo[3.1.0]hexane-2-carbonyl)-2-methyl-piperidine- 4-carbonyl)-2-methyl-1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluoro-N-isopropyl-N-(2,2,2- trifluoroethyl)benzamide [Example 53-4];(1-((1S,2S,5R)-3-Azabicyclo[3.1.0]hexane-2-carbonyl)piperidin-4-yl)(1-(4-fluoro-2-(4- isopropylpyridin-3-yl)phenyl)-2-methyl- 1H-pyrrolo[2,3-c]pyridin-3-yl)methanone [Example 54] ;2-(3-(1-((1S,2S,5R)-3-Azabicyclo[3.1.0]hexane-2-carbonyl)piperidine-4-carbonyl)-2-methyl- 1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluoro-N,N-diisopropylbenzamide [Example 55-2];(S)-2-(3-(1-(5,5-Dimethylpyrrolidine-2-carbonyl)piperidine-4-carbonyl)-2-methyl-1H- pyrrolo[2,3-c]pyridin-1-yl)-5-fluoro-N,N-diisopropylbenzamide [Example 56-2];2-(3-(1-((1S,2S,5R)-3-Azabicyclo[3.1.0]hexane-2-carbonyl)piperidine-4-carbonyl)-2-methyl- 1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluoro-N-isopropyl-N-((R)-l,l,l-trifluoropropan-2-yl)benzamide [Example 57-1];(1-((S)-4-Azaspiro[2.4]heptane-5-carbonyl)piperidin-4-yl)(1-(2-((3R,5R)-3,5- dimethylmorpholine-4-carbonyl)-4-fluorophenyl)-2-methyl-1H-pyrrolo[2,3-c]pyridin-3- yl)methanone [Example 58-2];(S)-2-(3-(1-(5,5-Dimethylpyrrolidine-2-carbonyl)piperidine-4-carbonyl)-2-methyl-1H- pyrrolo[2,3-c]pyridin-1-yl)-5-fluoro-N,N-bis(propan-2-yl-d7)benzamide [Example 59];5-Fluoro-N,N-diisopropyl-2-(2-methyl-3-(1-((2S,5S)-5-methylpyrrolidine-2- carbonyl)piperidine-4-carbonyl)- 1H-pyrrolo[2,3-c]pyridin- 1 -yl)benzamide [Example 60] ;5-Fluoro-N,N-diisopropyl-2-(2-methyl-3-(1-((2S,5R)-5-methylpyrrolidine-2- carbonyl)piperidine-4-carbonyl)- 1H-pyrrolo[2,3-c]pyridin- 1 -yl)benzamide [Example 61];5-Fluoro-N,N-diisopropyl-2-(2-methyl-3-((2S,4RS)-2-methyl-1-((2S,5S)-5- methylpyrrolidine-2-carbonyl)piperidine-4-carbonyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamide [Example 62] ;N-Ethyl-5-fluoro-N-isopropyl-2-(2-methyl-3-((2S,4RS)-2-methyl-1-((2S,5S)-5- methylpyrrolidine-2-carbonyl)piperidine-4-carbonyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamide [Example 63];5-Fluoro-N,N-diisopropyl-2-(2-methyl-3-((2S,4RS)-2-methyl-1-((2S,5R)-5- methylpyrrolidine-2-carbonyl)piperidine-4-carbonyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamide [Example 64] ; andN-Ethyl-5-fluoro-N-isopropyl-2-(2-methyl-3-((2S,4RS)-2-methyl-1-((2S,5R)-5- methylpyrrolidine-2-carbonyl)piperidine-4-carbonyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamide [Example 65]; and pharmaceutically acceptable salts thereof.
29. A pharmaceutical composition comprising a compound of any of claims 1 to 28, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.
30. A method of treating or preventing a Menin-mediated condition in a subject suffering from or susceptible to the Menin-mediated condition, the method comprising administering to thesubject a therapeutically effective amount of a compound of any of claims 1 to 28, or a pharmaceutically acceptable salt thereof.
